Parkinson's Disease

How does α-synuclein propagate from cell to cell? 1:37
How does α-synuclein propagate from cell to cell?
Tiago Outeiro • 18 Mar 2022
α-synuclein conformation as a novel blood biomarker in Parkinson’s disease 3:07
α-synuclein conformation as a novel blood biomarker in Parkinson’s disease
Tim Bartels • 17 Mar 2022
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline 1:54
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline
Tiago Outeiro • 18 Mar 2022
Sleep as a biomarker for neurodegenerative disorders 1:02
Sleep as a biomarker for neurodegenerative disorders
Emmanuel Mignot • 14 Mar 2022
Potential targets for Parkinson’s disease treatment 1:09
Potential targets for Parkinson’s disease treatment
Fabrizio Stocchi • 18 Mar 2022
Latest developments in symptomatic treatment of Parkinson’s disease 1:47
Latest developments in symptomatic treatment of Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Aberrant synuclein-lipid binding in Lewy body formation 2:09
Aberrant synuclein-lipid binding in Lewy body formation
Tim Bartels • 17 Mar 2022
Impact of α-synuclein on synaptic function 1:17
Impact of α-synuclein on synaptic function
Tiago Outeiro • 18 Mar 2022
Epigenomic and epitranscriptomic effects of α-synuclein in the nucleus 1:52
Epigenomic and epitranscriptomic effects of α-synuclein in the nucleus
Tiago Outeiro • 18 Mar 2022
Artificial intelligence in MRI processing for iRBD 2:34
Artificial intelligence in MRI processing for iRBD
Rahul Gaurav • 15 Mar 2022
Neurodegenerative changes to the substantia nigra in parkinsonism: iron accumulation 1:37
Neurodegenerative changes to the substantia nigra in parkinsonism: iron accumulation
Rahul Gaurav • 15 Mar 2022
iRBD prodrome diagnosis in α-synucleinopathies: an opportunity for neuroprotective intervention 2:17
iRBD prodrome diagnosis in α-synucleinopathies: an opportunity for neuroprotective intervention
Alex Iranzo • 15 Mar 2022
Neurodegenerative changes to the substantia nigra in parkinsonism – volume reduction 1:14
Neurodegenerative changes to the substantia nigra in parkinsonism – volume reduction
Rahul Gaurav • 15 Mar 2022
The importance of disease modifying therapy in iRBD 2:45
The importance of disease modifying therapy in iRBD
Aleksandar Videnovic • 24 Mar 2022
Alterations in circadian signaling in movement disorders 2:33
Alterations in circadian signaling in movement disorders
Aleksandar Videnovic • 24 Mar 2022
AI: predicting disease progression from EEG abnormalities in iRBD 3:09
AI: predicting disease progression from EEG abnormalities in iRBD
Matteo Cesari • 14 Mar 2022
The content of VJNeurology is intended for healthcare professionals